On February 17, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that, according to the latest quarterly index series released by Hang Seng Indexes Co., Ltd., ImmuneOnco was included in the Hang Seng Composite Index constituent stocks, which will officially take effect on March 4 (Monday) this year.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that, Dr. Tian Wenzhi, the company's founder and chairman

On February 16, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the research team of ImmuneOnco completed the preclinical study of IMM2902. The results were published in "Drug Resistance Updates" under the title "Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy".

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the founder and chairman of ImmunueOnco, Dr. Tian, Wenzhi, will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8th -11th, 2024 and deliver a speech at the Biotech Showcase™ held at the same time, comprehensively demonstrate ImmuneOnco’s innovative product pipeline and progress in clinical research and development.

On October 27, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that 2 drug candidates independently developed by the company, IMM2510, a bispecific antibody-receptor recombinant protein targeting PD-L1/VEGFA and IMM27M, an ADCC-enhanced CTLA-4 monoclonal antibody, are proposed to combined for the treatment of advanced solid tumors.